Literature DB >> 27776667

Dynamic contrast-enhanced case-control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness.

Roberto Sanz-Requena1, Luis Martí-Bonmatí2, Rosario Pérez-Martínez3, Gracián García-Martí4.   

Abstract

PURPOSE: The aim of this work is to establish normality and tumor tissue ranges for perfusion parameters from dynamic contrast-enhanced (DCE) MR of the peripheral prostate at 3T and to compare the diagnostic performance of quantitative and semi-quantitative parameters.
MATERIALS AND METHODS: Thirty-six patients with prostate carcinomas (18 Gleason-6, 15 Gleason-7, and 3 Gleason-8) and 33 healthy subjects were included. Image analysis workflow comprised four steps: manual segmentation of whole prostate and lesions, series registration, voxelwise T1 mapping and calculation of pharmacokinetic and semi-quantitative parameters.
RESULTS: Ktrans, ve, upslope and AUC60 showed statistically significant differences between healthy peripheral areas and tumors. Curve type showed no association with healthy/tumor peripheral areas (chi-square=0.702). Areas under the ROC curves were 0.64 (95% CI: 0.54-0.75), 0.70 (0.60-0.80), 0.62 (0.51-0.72) and 0.63 (0.52-0.74) for Ktrans, ve, upslope and AUC60, respectively. The optimal cutoff values were: Ktrans=0.21min-1 (sensitivity=0.61, specificity=0.64), ve=0.36 (0.63, 0.71), upslope=0.59 (0.59, 0.59) and AUC60=2.4 (0.63, 0.64). Significant differences were found between Gleason scores 6 and 7 for normalized Ktrans, upslope and AUC60, with good diagnostic accuracy (area under ROC curve 0.80, 95% CI: 0.60-1.00).
CONCLUSION: Quantitative (Ktrans and ve) and semi-quantitative (upslope and AUC60) perfusion parameters showed significant differences between tumors and control areas in the peripheral prostate. Normalized Ktrans, upslope and AUC60 values might characterize tumor aggressiveness.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; MRI; Neoplasms; Perfusion; Prostate; Standardization

Mesh:

Substances:

Year:  2016        PMID: 27776667     DOI: 10.1016/j.ejrad.2016.09.022

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?

Authors:  Daniel Junker; Fabian Steinkohl; Veronika Fritz; Jasmin Bektic; Theodoros Tokas; Friedrich Aigner; Thomas R W Herrmann; Michael Rieger; Udo Nagele
Journal:  World J Urol       Date:  2018-08-04       Impact factor: 4.226

2.  Robust and efficient pharmacokinetic parameter non-linear least squares estimation for dynamic contrast enhanced MRI of the prostate.

Authors:  Soudabeh Kargar; Eric A Borisch; Adam T Froemming; Akira Kawashima; Lance A Mynderse; Eric G Stinson; Joshua D Trzasko; Stephen J Riederer
Journal:  Magn Reson Imaging       Date:  2017-12-24       Impact factor: 2.546

3.  The impact of injector-based contrast agent administration in time-resolved MRA.

Authors:  Johannes Budjan; Ulrike I Attenberger; Stefan O Schoenberg; Hubertus Pietsch; Gregor Jost
Journal:  Eur Radiol       Date:  2017-12-07       Impact factor: 5.315

4.  Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate-Can We Make Better Use of It?

Authors:  Silva Guljaš; Mirta Benšić; Zdravka Krivdić Dupan; Oliver Pavlović; Vinko Krajina; Deni Pavoković; Petra Šmit Takač; Matija Hranić; Tamer Salha
Journal:  Tomography       Date:  2022-06-09

5.  Dynamic contrast-enhanced and diffusion-weighted MR imaging in the characterisation of small, non-palpable solid testicular tumours.

Authors:  Lucia Manganaro; Matteo Saldari; Carlotta Pozza; Valeria Vinci; Daniele Gianfrilli; Ermanno Greco; Giorgio Franco; Maria Eleonora Sergi; Michele Scialpi; Carlo Catalano; Andrea M Isidori
Journal:  Eur Radiol       Date:  2017-08-30       Impact factor: 5.315

6.  Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.

Authors:  Lili Xu; Gumuyang Zhang; Bing Shi; Yanhan Liu; Tingting Zou; Weigang Yan; Yu Xiao; Huadan Xue; Feng Feng; Jing Lei; Zhengyu Jin; Hao Sun
Journal:  Cancer Imaging       Date:  2019-12-21       Impact factor: 3.909

7.  The Assessment of Prostate Cancer Aggressiveness Using a Combination of Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Authors:  Guangbin Zhu; Jinwen Luo; Zhongmin Ouyang; Zenglan Cheng; Yi Deng; Yubao Guan; Guoxin Du; Fengjin Zhao
Journal:  Cancer Manag Res       Date:  2021-07-02       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.